SCHEMBL12907223

SCHEMBL12907223

Nc1n[nH]c2ccc(-c3ccc(Oc4ccccc4)cc3)cc12

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 14/20 0.77
JAK3 P52333 4/20 0.55
TYK2 P29597 3/20 0.55
JAK1 P23458 1/20 0.55
BTK Q06187 2/20 0.52
ROCK2 O75116 4/20 0.50
CDK2 P24941 4/20 0.50
AURKB Q96GD4 4/20 0.50
MAP4K4 O95819 3/20 0.50
CLK4 Q9HAZ1 3/20 0.50
CDC7 O00311 3/20 0.50
KDR P35968 3/20 0.50
DAPK3 O43293 3/20 0.50
CDK1 P06493 3/20 0.50
MARK3 P27448 3/20 0.50
CDK5 Q00535 3/20 0.50
PRKCD Q05655 3/20 0.50
ROCK1 Q13464 3/20 0.50
DYRK1A Q13627 3/20 0.50
PRKD2 Q9BZL6 3/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1336620 0.89 JAK2 (0.58) JAK2JAK3TYK2JAK1BTK
SCHEMBL1336206 0.89 JAK2 (0.58) JAK2JAK3TYK2JAK1BTK
SCHEMBL921766 0.88 JAK2 (0.77) JAK2BTKAURKBKDRROCK1
SCHEMBL3359889 0.87 JAK2 (1.00) JAK2JAK3TYK2JAK1ROCK2
SCHEMBL12907246 0.87 JAK2 (1.00) JAK2JAK3TYK2JAK1ROCK2
SCHEMBL12907173 0.83 JAK2 (0.60) JAK2JAK3TYK2JAK1BTK
SCHEMBL10213929 0.82 JAK2 (0.81) JAK2JAK3TYK2JAK1ROCK2
SCHEMBL12907168 0.81 PRKAG1 (0.68) JAK2JAK3TYK2JAK1ROCK2
SCHEMBL31240330 0.78 JAK2 (0.50) JAK2JAK3TYK2JAK1BTK
SCHEMBL12907183 0.78 JAK2 (0.60) JAK2JAK3TYK2JAK1ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7872039-B2 N-3-chlorobenzyl-3-amino-1H-indazole-5-carboxamide; 3-aminoindazoles; glucocorticoid-depedent kinase (SGK) inhibitors; SGK-induced diseases; diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, fibrosis; inflammatory agents MERCK PATENT GESELLSCHAFT (DE) 2011-01-18 US disclosed
US-7872039-B2 N-3-chlorobenzyl-3-amino-1H-indazole-5-carboxamide; 3-aminoindazoles; glucocorticoid-depedent kinase (SGK) inhibitors; SGK-induced diseases; diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, fibrosis; inflammatory agents MERCK PATENT GESELLSCHAFT (DE) 2011-01-18 US disclosed
EP-1765788-B1 3-AMINOINDAZOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SGK-ASSOCIATED DISEASES MERCK PATENT GMBH (DE) 2009-06-03 EP disclosed
US-20070232620-A1 3-Aminoindazoles MERCK PATENT GMBH (DE) 2007-10-04 US disclosed
US-20070232620-A1 3-Aminoindazoles MERCK PATENT GMBH (DE) 2007-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232620-A1 3-Aminoindazoles SGK3, SGK1, SGK2 JAK2 562/4885JAK3 180/4885TYK2 140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.